FDA Beats Spectrum Suit Over Fusilev Exclusivity At DC Circ.
The U.S. Food and Drug Administration acted reasonably when it approved Sandoz Inc.'s generic version of Spectrum Pharmaceuticals Inc.'s specialty drug Fusilev despite unexpired exclusivity for one indication, the D.C. Circuit...To view the full article, register now.
Already a subscriber? Click here to view full article